1. Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.
- Author
-
Ricardo Martinez, Alessandra Blasina, Jill F Hallin, Wenyue Hu, Isha Rymer, Jeffery Fan, Robert L Hoffman, Sean Murphy, Matthew Marx, Gina Yanochko, Dusko Trajkovic, Dac Dinh, Sergei Timofeevski, Zhou Zhu, Peiquing Sun, Patrick B Lappin, and Brion W Murray
- Subjects
Medicine ,Science - Abstract
Cell cycle checkpoint intervention is an effective therapeutic strategy for cancer when applied to patients predisposed to respond and the treatment is well-tolerated. A critical cell cycle process that could be targeted is the mitotic checkpoint (spindle assembly checkpoint) which governs the metaphase-to-anaphase transition and insures proper chromosomal segregation. The mitotic checkpoint kinase Mps1 was selected to explore whether enhancement in genomic instability is a viable therapeutic strategy. The basal-a subset of triple-negative breast cancer was chosen as a model system because it has a higher incidence of chromosomal instability and Mps1 expression is up-regulated. Depletion of Mps1 reduces tumor cell viability relative to normal cells. Highly selective, extremely potent Mps1 kinase inhibitors were created to investigate the roles of Mps1 catalytic activity in tumor cells and normal physiology (PF-7006, PF-3837; Ki
- Published
- 2015
- Full Text
- View/download PDF